Latest Response Biomedical (RPBIF) Headlines Re
Post# of 3
Posted On: 03/11/2014 5:37:41 AM
Latest Response Biomedical (RPBIF) Headlines
Response Biomedical Corp. Schedules Fourth Quarter and Fiscal Year 2013 Earnings Release and Conference Call
Marketwire - Thu Mar 06, 2:45PM CST
Response Biomedical Corp. ("Response") (TSX: RBM) (OTCBB: RPBIF) will release its fourth quarter and fiscal year 2013 financial results after the markets close on Thursday, March 13, 2014.
Response Biomedical Corp. Secures US$2.5 Million Term Loan
Marketwire - Tue Feb 11, 8:03PM CST
Response Biomedical Corp. (TSX: RBM)(OTCBB: RPBIF) ("Response" or the "Company") today announced that it has secured a US$2.5 million term loan from Silicon Valley Bank ("SVB"). The Company will initially draw down US$1.5 million of the facility, and a further US$1.0 million will become available for draw down if certain financial targets are met on or before July 31, 2014. The Company plans to use the funds from the loan to support working capital needs for growing its markets both in the U.S. and internationally, and for general corporate purposes.
Response Biomedical Corp. Provides Update on Chinese Distribution Agreement with O&D Biotech Co., Ltd.
Marketwire - Thu Jan 02, 7:00PM CST
Response Biomedical Corp. (TSX: RBM)(OTCBB: RPBIF) ("Response" or the "Company") today announced that its existing Chinese Distribution Agreement with O&D Biotech Co., Ltd. ("O&D") dated February 21, 2011, as amended, has expired effective December 31, 2013. The Company is currently in discussions with O&D regarding a new agreement whereby O&D could continue to market Response's cardiovascular products under their own brand labels and registrations; however, there can be no assurance that a new agreement will be executed.
Response Biomedical Corp. Announces Expansion of Chinese Distribution for RAMP(R) Cardiovascular Products
Marketwire - Mon Nov 25, 5:57PM CST
Response Biomedical Corp. ("Response" or the "Company") (TSX: RBM)(OTCBB: RPBIF) today announced that it has entered into agreements to distribute its Cardiovascular portfolio of RAMP(R) products with two new distributors in China, doubling Response's total number of distributors in a country that represents more than 60% of Response's worldwide sales. These new distribution agreements follow the approval of Response's RAMP(R) branded cardiovascular Point of Care Testing ("POCT") portfolio by the China Food and Drug Administration ("CFDA").
Response Biomedical Corp. Announces 2013 Third Quarter Financial Results
Marketwire - Wed Nov 13, 4:02PM CST
Response Biomedical Corp. ("Response" or the "Company") (TSX: RBM)(OTCBB: RPBIF) today reported financial results for the quarter and nine months ended September 30, 2013.
Response Biomedical Corp. Announces Conversion of Subscription Receipts
Marketwire - Thu Nov 07, 4:50PM CST
Response Biomedical Corp. ("Response" or the "Company") (TSX: RBM)(OTCBB: RPBIF) is pleased to announce that shareholders of Response have approved the conversion of 1,273,117 subscription receipts (the "Subscription Receipts") for gross proceeds of approximately $3.1 million. The Subscription Receipts were issued in connection with the Company's previously announced brokered and non-brokered private placements (the "Offering").
Response Biomedical Corp. Schedules Third Quarter 2013 Earnings Release and Conference Call and Announces Participation in Upcoming Investor Conferences
Marketwire - Wed Nov 06, 6:02PM CST
Response Biomedical Corp. (TSX: RBM)(OTCBB: RPBIF) ("Response") will release its third quarter 2013 financial results after the markets close on Wednesday, November 13, 2013.
Response Biomedical Corp. Announces New U.S. Sales Representation Agreement With Med Tech/Med Care
Marketwire - Thu Oct 31, 6:45AM CDT
Response Biomedical Corp. (TSX: RBM)(OTCBB: RPBIF) ("Response" or the "Company") announced today that it has entered into a sales representation agreement with Med Tech/Med Care, a large, outsourced sales organization to provide sales and marketing representation of its RAMP(R)-branded Cardiovascular and Infectious Disease testing line in the U.S. Med Tech/Med Care provides national coverage to U.S. hospitals and hospital owned affiliates. Med Tech/Med Care maintains offices in both Massachusetts and Colorado.
Response Biomedical Corp. Announces 2013 Second Quarter Financial Results
Marketwire - Tue Aug 13, 4:01PM CDT
Response Biomedical Corp. ("Response") (TSX: RBM)(OTCBB: RPBIF) today reported financial results for the quarter and six months ended June 30, 2013.
Response Biomedical Corp. Schedules Second Quarter 2013 Earnings Release and Announces Conference Call
Marketwire - Wed Aug 07, 5:39PM CDT
Response Biomedical Corp. ("Response") (TSX: RBM)(OTCBB: RPBIF) will release its second quarter 2013 financial results after the markets close on August 13, 2013.
Response Biomedical Corp. Schedules Fourth Quarter and Fiscal Year 2013 Earnings Release and Conference Call
Marketwire - Thu Mar 06, 2:45PM CST
Response Biomedical Corp. ("Response") (TSX: RBM) (OTCBB: RPBIF) will release its fourth quarter and fiscal year 2013 financial results after the markets close on Thursday, March 13, 2014.
Response Biomedical Corp. Secures US$2.5 Million Term Loan
Marketwire - Tue Feb 11, 8:03PM CST
Response Biomedical Corp. (TSX: RBM)(OTCBB: RPBIF) ("Response" or the "Company") today announced that it has secured a US$2.5 million term loan from Silicon Valley Bank ("SVB"). The Company will initially draw down US$1.5 million of the facility, and a further US$1.0 million will become available for draw down if certain financial targets are met on or before July 31, 2014. The Company plans to use the funds from the loan to support working capital needs for growing its markets both in the U.S. and internationally, and for general corporate purposes.
Response Biomedical Corp. Provides Update on Chinese Distribution Agreement with O&D Biotech Co., Ltd.
Marketwire - Thu Jan 02, 7:00PM CST
Response Biomedical Corp. (TSX: RBM)(OTCBB: RPBIF) ("Response" or the "Company") today announced that its existing Chinese Distribution Agreement with O&D Biotech Co., Ltd. ("O&D") dated February 21, 2011, as amended, has expired effective December 31, 2013. The Company is currently in discussions with O&D regarding a new agreement whereby O&D could continue to market Response's cardiovascular products under their own brand labels and registrations; however, there can be no assurance that a new agreement will be executed.
Response Biomedical Corp. Announces Expansion of Chinese Distribution for RAMP(R) Cardiovascular Products
Marketwire - Mon Nov 25, 5:57PM CST
Response Biomedical Corp. ("Response" or the "Company") (TSX: RBM)(OTCBB: RPBIF) today announced that it has entered into agreements to distribute its Cardiovascular portfolio of RAMP(R) products with two new distributors in China, doubling Response's total number of distributors in a country that represents more than 60% of Response's worldwide sales. These new distribution agreements follow the approval of Response's RAMP(R) branded cardiovascular Point of Care Testing ("POCT") portfolio by the China Food and Drug Administration ("CFDA").
Response Biomedical Corp. Announces 2013 Third Quarter Financial Results
Marketwire - Wed Nov 13, 4:02PM CST
Response Biomedical Corp. ("Response" or the "Company") (TSX: RBM)(OTCBB: RPBIF) today reported financial results for the quarter and nine months ended September 30, 2013.
Response Biomedical Corp. Announces Conversion of Subscription Receipts
Marketwire - Thu Nov 07, 4:50PM CST
Response Biomedical Corp. ("Response" or the "Company") (TSX: RBM)(OTCBB: RPBIF) is pleased to announce that shareholders of Response have approved the conversion of 1,273,117 subscription receipts (the "Subscription Receipts") for gross proceeds of approximately $3.1 million. The Subscription Receipts were issued in connection with the Company's previously announced brokered and non-brokered private placements (the "Offering").
Response Biomedical Corp. Schedules Third Quarter 2013 Earnings Release and Conference Call and Announces Participation in Upcoming Investor Conferences
Marketwire - Wed Nov 06, 6:02PM CST
Response Biomedical Corp. (TSX: RBM)(OTCBB: RPBIF) ("Response") will release its third quarter 2013 financial results after the markets close on Wednesday, November 13, 2013.
Response Biomedical Corp. Announces New U.S. Sales Representation Agreement With Med Tech/Med Care
Marketwire - Thu Oct 31, 6:45AM CDT
Response Biomedical Corp. (TSX: RBM)(OTCBB: RPBIF) ("Response" or the "Company") announced today that it has entered into a sales representation agreement with Med Tech/Med Care, a large, outsourced sales organization to provide sales and marketing representation of its RAMP(R)-branded Cardiovascular and Infectious Disease testing line in the U.S. Med Tech/Med Care provides national coverage to U.S. hospitals and hospital owned affiliates. Med Tech/Med Care maintains offices in both Massachusetts and Colorado.
Response Biomedical Corp. Announces 2013 Second Quarter Financial Results
Marketwire - Tue Aug 13, 4:01PM CDT
Response Biomedical Corp. ("Response") (TSX: RBM)(OTCBB: RPBIF) today reported financial results for the quarter and six months ended June 30, 2013.
Response Biomedical Corp. Schedules Second Quarter 2013 Earnings Release and Announces Conference Call
Marketwire - Wed Aug 07, 5:39PM CDT
Response Biomedical Corp. ("Response") (TSX: RBM)(OTCBB: RPBIF) will release its second quarter 2013 financial results after the markets close on August 13, 2013.
(0)
(0)Response Biomedical Corp (RPBIF) Stock Research Links
Scroll down for more posts ▼